Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

STOK

Stoke Therapeutics Inc

May 16 • 04:00PM ET

14.03

Dollar change -0.10
Percentage change -0.71	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN SCHA VTWO IWC VHT ITOT AVSC

Index	RUT	P/E	-	EPS (ttm)	-2.42	Insider Own	25.46%	Shs Outstand	45.92M	Perf Week	16.82%
Market Cap	731.24M	Forward P/E	-	EPS next Y	-2.60	Insider Trans	-20.03%	Shs Float	38.85M	Perf Month	19.71%
Income	-108.53M	PEG	-	EPS next Q	-0.55	Inst Own	76.52%	Short Float	21.39%	Perf Quarter	164.22%
Sales	7.84M	P/S	93.27	EPS this Y	4.34%	Inst Trans	-1.88%	Short Ratio	6.15	Perf Half Y	197.88%
Book/sh	3.02	P/B	4.65	EPS next Y	-14.23%	ROA	-44.57%	Short Interest	8.31M	Perf Year	25.04%
Cash/sh	3.43	P/C	4.09	EPS next 5Y	-	ROE	-61.29%	52W Range	3.35 - 16.40	Perf YTD	166.73%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-44.06%	ROI	-75.12%	52W High	-14.45%	Beta	0.88
Dividend TTM	-	Quick Ratio	5.42	Sales past 5Y	-5.84%	Gross Margin	40.15%	52W Low	318.81%	ATR (14)	1.00
Dividend Ex-Date	-	Current Ratio	5.42	EPS Y/Y TTM	2.14%	Oper. Margin	-1509.93%	RSI (14)	66.65	Volatility	8.40% 7.57%
Employees	110	Debt/Eq	0.05	Sales Y/Y TTM	-46.11%	Profit Margin	-1383.40%	Recom	1.22	Target Price	22.14
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	-7.60%	Payout	-	Rel Volume	0.56	Prev Close	14.13
Sales Surprise	29.31%	EPS Surprise	6.54%	Sales Q/Q	-18.17%	Earnings	May 06 BMO	Avg Volume	1.35M	Price	14.03
SMA20	18.15%	SMA50	31.30%	SMA200	121.37%	Trades		Volume	762,675	Change	-0.71%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-26-24	Upgrade	TD Cowen	Market Perform → Outperform
Nov-20-23	Resumed	JP Morgan	Neutral
Jul-25-23	Downgrade	TD Cowen	Outperform → Market Perform
May-01-23	Upgrade	BofA Securities	Underperform → Neutral	$9 → $12
Apr-26-23	Resumed	Canaccord Genuity	Buy	$24
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform	$22 → $9
Oct-24-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$30
Jan-31-22	Initiated	Jefferies	Buy	$50
Dec-03-21	Initiated	BofA Securities	Buy	$43
Nov-22-21	Upgrade	JP Morgan	Neutral → Overweight	$41
May-18-21	Initiated	UBS	Neutral	$35
May-10-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform	$58
Feb-10-21	Downgrade	Wedbush	Outperform → Neutral
Dec-15-20	Resumed	H.C. Wainwright	Buy	$70
Dec-11-20	Reiterated	Needham	Buy	$48 → $56
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight	$49
Sep-29-20	Resumed	JP Morgan	Neutral	$34
Sep-29-20	Initiated	Needham	Buy	$42
Dec-18-19	Initiated	Wedbush	Outperform	$31

Show Previous Ratings

May-07-24 09:04PM	Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ... (GuruFocus.com)
10:30AM	Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating (MT Newswires)
May-06-24 11:53AM	STOK Stock Earnings: Stoke Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:05AM	Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates (Business Wire)
10:21AM	Loading…
Apr-29-24 10:21AM	Stoke Therapeutics Appoints Thomas Leggett CFO (MT Newswires)
08:00AM	Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer (Business Wire)
Apr-25-24 10:01AM	Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline (Zacks)
Apr-23-24 07:45AM	Garry Menzel joins GHO Capital as Operating Partner (GlobeNewswire)
Apr-17-24 08:00AM	Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer (Business Wire) -5.86%
Apr-04-24 04:30PM	Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference (Business Wire) -5.03%
Mar-27-24 11:40PM	Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering (Business Wire) +37.71%
08:50AM	Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data (Zacks)
Mar-26-24 04:07PM	Stoke Therapeutics Announces Proposed Public Offering (Business Wire) +58.31%
11:20AM	Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients (Benzinga)
07:54AM	Loading…
07:54AM	Why Is Stoke Therapeutics (STOK) Stock Up 99% Today? (InvestorPlace)
07:49AM	Stoke shares surge on updated results for Dravet drug (BioPharma Dive)
Mar-25-24 09:53PM	STOK Stock Earnings: Stoke Therapeutics Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:10PM	Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
04:01PM	Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome (Business Wire)
Feb-29-24 08:50AM	Why Earnings Season Could Be Great for Stoke Therapeutics (STOK) (Zacks)
Feb-26-24 10:00AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) +11.95%
Feb-25-24 01:37PM	7 Biotech Penny Stocks on the Verge of Clinical Trial Victory (InvestorPlace)
Feb-19-24 02:31PM	Triple Threat: 3 Stocks to Buy for 3X Upside Potential (InvestorPlace)
Feb-15-24 09:55AM	Does Stoke Therapeutics, Inc. (STOK) Have the Potential to Rally 284.14% as Wall Street Analysts Expect? (Zacks)
06:59AM	Stoke Therapeutics, Inc. (STOK) Stock Jumps 25.5%: Will It Continue to Soar? (Zacks)
Jan-17-24 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jan-08-24 08:00AM	Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024 (Business Wire)
Jan-04-24 04:30PM	Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
10:29AM	Loading…
Jan-02-24 10:29AM	Why healthcare, biotech may be top plays for 2024: BTIG (Yahoo Finance Video) +11.41%
Dec-14-23 09:55AM	Wall Street Analysts Predict a 220.81% Upside in Stoke Therapeutics, Inc. (STOK): Here's What You Should Know (Zacks)
Dec-01-23 09:00AM	Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting (Business Wire)
Nov-21-23 08:00AM	Stoke Therapeutics to Present Data from the Companys Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting (Business Wire) -6.47%
Nov-09-23 05:48AM	Stoke Therapeutics Inc (STOK) Reports Q3 Financial Results and Progress in Dravet Syndrome Treatment (GuruFocus.com)
Nov-07-23 07:00AM	Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates (Business Wire) +12.53%
Oct-17-23 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Sep-21-23 08:00AM	Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference (Business Wire) -6.53%
Sep-20-23 04:30PM	Stoke Therapeutics Appoints Ian Smith to its Board of Directors (Business Wire) -6.72%
Sep-05-23 07:00AM	Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress (Business Wire)
Aug-16-23 01:00PM	This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street (Motley Fool)
Aug-08-23 06:02AM	Stoke Therapeutics Second Quarter 2023 Earnings: Misses Expectations (Simply Wall St.) -5.13%
Aug-07-23 08:15AM	Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates (Business Wire)
Aug-02-23 08:00AM	Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference (Business Wire)
Jul-25-23 02:32PM	Why Shares of Stoke Therapeutics Plummeted Tuesday (Motley Fool) -32.11%
07:00AM	Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome (Business Wire)
Jul-21-23 07:30AM	Stoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome (Business Wire) +7.73%
Jul-05-23 01:20PM	Here's Why We're Not Too Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation (Simply Wall St.)
Jun-21-23 04:22AM	Stoke Therapeutics, Inc. (STOK) Surges 6.3%: Is This an Indication of Further Gains? (Zacks)
Jun-16-23 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jun-14-23 09:55AM	Should You Buy Stoke Therapeutics, Inc. (STOK) After Golden Cross? (Zacks)
May-09-23 09:55AM	How Much Upside is Left in Stoke Therapeutics, Inc. (STOK)? Wall Street Analysts Think 102.91% (Zacks)
06:04AM	New Forecasts: Here's What Analysts Think The Future Holds For Stoke Therapeutics, Inc. (NASDAQ:STOK) (Simply Wall St.)
May-06-23 08:03AM	Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Boosting Their Estimates (Simply Wall St.)
May-04-23 10:00AM	Analysts Estimate Synlogic, Inc. (SYBX) to Report a Decline in Earnings: What to Look Out for (Zacks) +12.96%
08:55AM	Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates (Business Wire)
May-03-23 08:00AM	Stoke Therapeutics to Present at the BofA Securities Health Care Conference (Business Wire)
May-02-23 10:02AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-25-23 07:00AM	Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom (Business Wire)
Mar-28-23 10:40AM	Investors in Stoke Therapeutics (NASDAQ:STOK) have unfortunately lost 64% over the last three years (Simply Wall St.)
Mar-15-23 07:00AM	Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome (Business Wire) -6.92%
Mar-06-23 08:15AM	Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (Business Wire)
Feb-27-23 04:30PM	Stoke Therapeutics to Participate at Upcoming March Investor Conferences (Business Wire)
Feb-07-23 08:00AM	Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference (Business Wire)
Jan-26-23 05:59AM	Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth (Simply Wall St.)
Jan-09-23 08:00AM	Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023 (Business Wire)
Jan-04-23 08:00AM	Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire) +6.16%
Dec-02-22 09:00AM	Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting (Business Wire)
Nov-29-22 07:30AM	Stoke Therapeutics to Present Data from the Companys Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting (Business Wire)
Nov-14-22 01:02PM	Stoke Therapeutics Stock Falls Post Early Efficacy Data From Lead Dravet Syndrome Program (Benzinga) -25.30%
08:25AM	Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates (Business Wire)
Nov-10-22 08:32AM	Is a Surprise Coming for Stoke Therapeutics (STOK) This Earnings Season? (Zacks)
07:30AM	Stoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet Syndrome (Business Wire)
Nov-07-22 09:55AM	Stoke Therapeutics, Inc. (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Oct-19-22 10:02AM	Stoke Therapeutics (NASDAQ:STOK) adds US$56m to market cap in the past 7 days, though investors from a year ago are still down 43% (Simply Wall St.)
Aug-25-22 07:30AM	Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA) (Business Wire)
Aug-19-22 06:40AM	We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow (Simply Wall St.)
Aug-10-22 09:55AM	How Much Upside is Left in Stoke Therapeutics, Inc. (STOK)? Wall Street Analysts Think 91% (Zacks)
Aug-09-22 11:54AM	7 Stocks Due for a Stunning Short Squeeze (InvestorPlace)
Aug-08-22 08:15AM	Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +26.03%
07:00AM	Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates (Business Wire)
Jun-01-22 02:00PM	Scientist needed to come out as gay before founding a biotech (American City Business Journals)
07:30AM	Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference (Business Wire)
May-12-22 07:44AM	Stoke Therapeutics (NASDAQ:STOK shareholders incur further losses as stock declines 15% this week, taking one-year losses to 64% (Simply Wall St.) +5.95%
May-10-22 07:00AM	Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates (Business Wire) +7.96%
May-05-22 10:06AM	Acadia (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates (Zacks) -7.32%
May-02-22 04:35PM	Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002 (Business Wire)
Apr-07-22 07:30AM	Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting (Business Wire)
Apr-05-22 07:30AM	Stoke Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-10-22 07:00AM	Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates (Business Wire)
Mar-01-22 09:43AM	Acadia (ACAD) Q4 Earnings & Revenues Fall Shy of Estimates (Zacks)
Feb-28-22 10:00AM	Wall Street Analysts Believe Stoke Therapeutics, Inc. (STOK) Could Rally 184%: Here's is How to Trade (Zacks)
07:30AM	Stoke Therapeutics to Participate in the Cowen 42nd Annual Health Care Conference (Business Wire)
Feb-10-22 10:00AM	Wall Street Analysts See a 192% Upside in Stoke Therapeutics, Inc. (STOK): Can the Stock Really Move This High? (Zacks)
Jan-13-22 11:13AM	Acadia (ACAD) Up More Than 20% in Past 3 Months: Here's Why (Zacks)
Jan-11-22 11:56AM	Acadia (ACAD) Partners With Stoke for CNS Disorder Therapies (Zacks)

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ticho Barry	CHIEF MEDICAL OFFICER	May 01 '24	Option Exercise	0.60	10,000	6,000	12,485	May 03 04:24 PM
Ticho Barry	CHIEF MEDICAL OFFICER	May 01 '24	Sale	11.37	10,000	113,653	2,485	May 03 04:24 PM
Skorpios Trust	10% Owner	Apr 17 '24	Sale	11.60	3,600,000	41,760,000	10,843,681	Apr 18 04:16 PM
Nash Huw M.	COO & CBO	Apr 01 '24	Option Exercise	0.40	50,000	20,000	61,329	Apr 03 04:19 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Apr 01 '24	Option Exercise	0.60	442	265	11,911	Apr 03 04:21 PM
Nash Huw M.	COO & CBO	Apr 01 '24	Sale	13.23	61,329	811,212	0	Apr 03 04:19 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Apr 01 '24	Sale	13.23	9,426	124,684	2,485	Apr 03 04:21 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 28 '24	Sale	13.20	5,126	67,668	2,598	Apr 01 04:14 PM
Kaye Edward M. MD	CEO	Mar 19 '24	Sale	6.10	11,150	67,999	69,350	Mar 19 08:30 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 19 '24	Sale	6.10	4,116	25,102	11,469	Mar 19 08:34 PM
Nash Huw M.	COO & CBO	Mar 19 '24	Sale	6.10	4,116	25,102	11,329	Mar 19 08:31 PM
Tulipano Stephen J	CFO	Mar 19 '24	Sale	6.10	4,116	25,102	20,746	Mar 19 08:36 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 19 '24	Sale	6.10	2,349	14,326	7,724	Mar 19 08:29 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 15 '24	Option Exercise	0.00	13,100	0	15,585	Mar 19 08:34 PM
Tulipano Stephen J	CFO	Mar 15 '24	Option Exercise	0.00	13,100	0	24,862	Mar 19 08:36 PM
Nash Huw M.	COO & CBO	Mar 15 '24	Option Exercise	0.00	13,100	0	15,445	Mar 19 08:31 PM
Kaye Edward M. MD	CEO	Mar 15 '24	Option Exercise	0.00	35,500	0	80,500	Mar 19 08:30 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 15 '24	Option Exercise	0.00	7,475	0	10,073	Mar 19 08:29 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 01 '24	Option Exercise	0.60	5,504	3,302	12,485	Mar 05 04:21 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 01 '24	Sale	7.75	10,000	77,469	2,485	Mar 05 04:21 PM
TZIANABOS ARTHUR	Director	Feb 13 '24	Option Exercise	2.19	31,739	69,508	31,739	Feb 15 04:17 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Feb 01 '24	Sale	4.80	10,000	47,991	6,981	Feb 05 04:32 PM
Ticho Barry	Chief Medical Officer	Jan 02 '24	Sale	5.74	10,000	57,352	16,981	Jan 04 04:38 PM
Ticho Barry	Chief Medical Officer	Jul 03 '23	Sale	10.60	15,000	158,973	25,895	Jul 06 05:20 PM
Allan Jonathan	General Counsel & Corp Sec	Jun 21 '23	Sale	13.48	1,948	26,252	0	Jun 23 04:45 PM
Ticho Barry	Chief Medical Officer	Jun 01 '23	Sale	11.13	15,000	166,964	40,895	Jun 05 07:31 PM

Open in Screener

AKRO

Akero Therapeutics Inc

May 16 • 04:00PM ET

20.73

Dollar change -0.34
Percentage change -1.61	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

AKRO Akero Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IWO IBB SCHA SURI LABU VTWO VHT

Index	RUT	P/E	-	EPS (ttm)	-3.20	Insider Own	15.85%	Shs Outstand	69.15M	Perf Week	-0.34%
Market Cap	1.43B	Forward P/E	-	EPS next Y	-4.22	Insider Trans	0.21%	Shs Float	58.19M	Perf Month	-4.03%
Income	-179.27M	PEG	-	EPS next Q	-0.89	Inst Own	98.03%	Short Float	14.78%	Perf Quarter	-3.18%
Sales	0.00M	P/S	-	EPS this Y	-33.39%	Inst Trans	16.93%	Short Ratio	6.87	Perf Half Y	39.03%
Book/sh	12.24	P/B	1.69	EPS next Y	-9.41%	ROA	-28.43%	Short Interest	8.60M	Perf Year	-55.32%
Cash/sh	13.07	P/C	1.59	EPS next 5Y	-14.60%	ROE	-31.11%	52W Range	11.25 - 58.38	Perf YTD	-11.22%
Dividend Est.	-	P/FCF	-	EPS past 5Y	1.03%	ROI	-20.33%	52W High	-64.49%	Beta	-0.28
Dividend TTM	-	Quick Ratio	30.12	Sales past 5Y	0.00%	Gross Margin	-	52W Low	84.27%	ATR (14)	1.28
Dividend Ex-Date	-	Current Ratio	30.12	EPS Y/Y TTM	-17.00%	Oper. Margin	0.00%	RSI (14)	47.07	Volatility	7.15% 5.82%
Employees	56	Debt/Eq	0.04	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.20	Target Price	46.78
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	-63.47%	Payout	-	Rel Volume	0.37	Prev Close	21.07
Sales Surprise	-	EPS Surprise	0.24%	Sales Q/Q	-	Earnings	May 10 BMO	Avg Volume	1.25M	Price	20.73
SMA20	1.48%	SMA50	-10.89%	SMA200	-24.12%	Trades		Volume	457,700	Change	-1.61%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-24	Resumed	BofA Securities	Neutral	$30
Sep-19-23	Initiated	Cantor Fitzgerald	Overweight	$69
Aug-28-23	Initiated	UBS	Buy	$83
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$40 → $65
Sep-14-22	Upgrade	Evercore ISI	In-line → Outperform	$10 → $50
Oct-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$27
Sep-10-21	Initiated	BofA Securities	Buy	$40
Feb-26-21	Initiated	Guggenheim	Buy	$54
Sep-10-20	Initiated	Morgan Stanley	Overweight	$70
Jul-20-20	Reiterated	H.C. Wainwright	Buy	$45 → $62
Jul-07-20	Initiated	Chardan Capital Markets	Buy	$79
Jul-01-20	Reiterated	H.C. Wainwright	Buy	$33 → $45
Mar-02-20	Initiated	H.C. Wainwright	Buy	$33
Feb-10-20	Initiated	Canaccord Genuity	Buy	$36
Jul-15-19	Initiated	ROTH Capital	Buy	$34
Jul-15-19	Initiated	JP Morgan	Overweight	$28
Jul-15-19	Initiated	Jefferies	Buy	$28
Jul-15-19	Initiated	Evercore ISI	Outperform	$35

Show Previous Ratings

May-15-24 09:26AM	Evercore ISI Adjusts Price Target on Akero Therapeutics to $38 From $50, Maintains Outperform Rating (MT Newswires)
May-12-24 09:01PM	Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ... (GuruFocus.com)
May-10-24 01:54PM	AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -5.53%
07:45AM	Akero Therapeutics' Q1 Net Loss Widens; Cash Expected to Fund Operations Into H2 2027 (MT Newswires)
07:00AM	Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Loading…
May-08-24 07:00AM	Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference (GlobeNewswire)
Apr-30-24 08:00AM	Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer (GlobeNewswire)
Apr-22-24 06:00AM	6 Stocks Positioned to Soar as Investors Focus on MASH (News Direct)
Mar-20-24 01:32PM	Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks (Insider Monkey)
12:58PM	AKRO Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Akero Therapeutics (NASDAQ:AKRO) (GlobeNewswire)
Mar-18-24 07:00AM	Ozempic Cant Do It AllA Potential New Blockbuster Is a Reminder of That (The Wall Street Journal)
Mar-08-24 04:02PM	Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Mar-07-24 04:01PM	Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology (GlobeNewswire)
Mar-06-24 11:54PM	President and CEO Andrew Cheng Sells 75,000 Shares of Akero Therapeutics Inc (AKRO) (GuruFocus.com)
Mar-05-24 09:13PM	Akero Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
02:12PM	Loading…
02:12PM	Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study (Zacks)
Mar-04-24 04:21PM	Akero Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +11.72%
04:04PM	Why Akero Rocketed And Pulled Rival 89bio Higher On Results In Liver Disease Treatment (Investor's Business Daily)
12:30PM	Data Suggests Makers of Fatty Liver Treatments Wont Be Displaced by Obesity Drugs (The Wall Street Journal)
11:59AM	Akero Therapeutics Bats Back Challenge From Lilly in Emerging Liver-Drug Market (Barrons.com)
09:23AM	Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment (Investor's Business Daily)
06:22AM	UPDATE 1-Akero's lead drug helps reduce scarring in fatty liver disease patients (Reuters)
06:09AM	Akero's lead drug helps improve scarring in fatty liver disease patients (Reuters)
06:00AM	Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study (GlobeNewswire)
04:00AM	Akero strengthens MASH drugs case with new study data (BioPharma Dive)
Mar-01-24 09:55AM	Wall Street Analysts Predict a 58.87% Upside in Akero Therapeutics, Inc. (AKRO): Here's What You Should Know (Zacks)
Feb-29-24 08:00AM	Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH (GlobeNewswire)
07:00AM	Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-06-24 10:48AM	Cramer's Stop Trading: Akero Therapeutics (CNBC TV) -12.25%
Feb-05-24 09:55AM	Here's Why Akero Therapeutics, Inc. (AKRO) Is a Great 'Buy the Bottom' Stock Now (Zacks)
09:40AM	Loading…
Jan-30-24 09:40AM	Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.22%
Jan-03-24 08:15AM	Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.41%
Dec-18-23 07:00AM	Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program (GlobeNewswire)
Dec-13-23 03:06AM	Insider Sell Alert: Akero Therapeutics Inc's President and CEO Andrew Cheng Disposes of 26,978 ... (GuruFocus.com)
Dec-05-23 01:34PM	12 Most Promising Stocks to Buy According to Hedge Funds (Insider Monkey)
12:36PM	Hedge Fund and Insider Trading News: Jeff Ubben, Bill Ackman, Saba Capital Management, Akero Therapeutics Inc (AKRO), Verizon Communications Inc. (VZ) and More (Insider Monkey)
Nov-14-23 07:21PM	Akero Therapeutics Inc (AKRO) Reports Q3 2023 Financial Results (GuruFocus.com)
Nov-13-23 07:00AM	Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-10-23 08:57AM	Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD's The Liver Meeting 2023 (GlobeNewswire)
Nov-08-23 07:00AM	Akero Therapeutics to Present at Upcoming Healthcare Conferences in November (GlobeNewswire)
Oct-17-23 04:05PM	Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference (GlobeNewswire)
Oct-12-23 04:38PM	Why Akero Therapeutics Shares Are Slumping This Week (Motley Fool)
08:24AM	Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback (Zacks)
Oct-11-23 05:35PM	Akero Therapeutics' Lead Candidate Potential: Analyst Unpacks Complicated Regulatory Path Forward (Benzinga) -17.13%
11:11AM	Akero (AKRO) Slumps 63% on Mixed Results From NASH Study (Zacks)
Oct-10-23 04:13PM	Why Shares of 89bio Plummeted on Tuesday (Motley Fool) -62.61%
04:03PM	Why Akero Therapeutics Lost More Than Half Its Value And Dragged Down 89bio (Investor's Business Daily)
12:10PM	PepsiCo, Palantir rise; Neogen, Akero Therapeutics fall, Tuesday, 10/10/2023 (Associated Press Finance)
11:44AM	Why Akero Therapeutics Stock Is Crashing Today (Motley Fool)
10:37AM	Akero Therapeutics, Palantir, Hyatt Hotels: Trending tickers (Yahoo Finance Video)
09:29AM	Why Is Akero Therapeutics (AKRO) Stock Down 58% Today? (InvestorPlace)
07:15AM	Akero's drug for fatty liver disease misses main trial goal (Reuters)
07:00AM	Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins (GlobeNewswire)
Oct-09-23 04:05PM	Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH (GlobeNewswire)
Oct-05-23 07:01AM	Insider Sell: Akero Therapeutics Inc CEO Andrew Cheng Sells 25,000 Shares (GuruFocus.com)
Oct-04-23 08:00AM	Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology (GlobeNewswire)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-27-23 09:24PM	7 Strong Buy Biotech Stocks to Rejuvenate Your Portfolio (InvestorPlace)
Sep-14-23 07:56AM	Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA (Zacks)
Aug-31-23 07:00AM	Akero Therapeutics to Present at Upcoming Healthcare Conferences in September (GlobeNewswire)
Aug-28-23 07:00AM	Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023 (GlobeNewswire)
Aug-11-23 06:00AM	Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +6.59%
Jul-11-23 09:02AM	Infinity Pharma (INFI) Stock Up on Advancing Cancer Study (Zacks)
Jul-10-23 09:32AM	Viking Therapeutics (VKTX) Surges 64% Year to Date: Here's Why (Zacks)
09:29AM	Sotherly Hotels' (SOHO) Q2 Operating Trend Reflects Solid Demand (Zacks)
08:58AM	Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study (Zacks)
Jul-07-23 08:00AM	Obesity Drugs Wont Starve These Other Potential Blockbusters (The Wall Street Journal)
07:46AM	Ultragenyx (RARE) Doses First Patients in Bone Disease Studies (Zacks)
Jul-03-23 11:20AM	Baudax Bio (BXRX) Up 125% on Acquiring TeraImmune (Zacks)
10:25AM	Alnylam (ALNY) Announces FDA Committee Onpattro sNDA Review Date (Zacks)
Jul-01-23 09:00AM	Top Stocks for July 2023 (Investopedia)
Jun-29-23 10:04AM	Esperion (ESPR) to Expand Nilemdo and Nustendi Label in Europe (Zacks)
09:59AM	Axsome (AXSM) Down on Public Offering of Common Stock (Zacks)
09:18AM	Reata's (RETA) Skyclarys PAS Gets FDA Nod, Stock Rises 7% (Zacks)
Jun-28-23 10:53AM	Amicus (FOLD) Gets Approval in Europe for Pompe Disease Drug (Zacks)
Jun-27-23 01:47PM	Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint (Zacks)
Jun-26-23 11:23AM	AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval (Zacks) -9.17%
11:15AM	Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data (Zacks)
10:36AM	Amylyx (AMLX) Down on Negative CHMP Opinion for ALS candidate (Zacks)
08:50AM	Recent Price Trend in Akero Therapeutics, Inc. (AKRO) is Your Friend, Here's Why (Zacks)
08:21AM	Pfizer's (PFE) Litfulo Receives FDA Nod for Alopecia Areata (Zacks)
06:41AM	Daily Vickers Top Buyers & Sellers for 06/26/2023 (Argus Research)
Jun-23-23 10:50AM	Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate (Zacks)
09:15AM	Horizon's (HZNP) Tepezza Study in Japan for TED Meets Goal (Zacks)
07:00AM	Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology (GlobeNewswire)
Jun-22-23 09:18AM	Alderya (ALDX) Stock Declines on Getting CRL for PVRL Candidate (Zacks)
Jun-21-23 03:21PM	Denali (DNLI) Provides Update on Hunter Syndrome Study (Zacks)
10:46AM	Merck's (MRK) Gastric Cancer Study Fails to Meet a Primary Goal (Zacks)
Jun-20-23 08:54AM	Verve (VERV) Up 9.9% in a Week on Collaboration With Eli Lilly (Zacks)
Jun-19-23 10:28AM	Reata (RETA) Announces FDA's Acceptance of Skyclarys PAS (Zacks)
10:18AM	GSK Announces Extension of FDA Review for Rare Blood Therapy (Zacks)
Jun-16-23 10:26AM	Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study (Zacks)
08:39AM	Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study (Zacks)
Jun-15-23 09:43AM	Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall (Zacks)
08:18AM	IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study (Zacks)
Jun-14-23 12:17PM	Can-Fite (CANF) Up on Namodenoson Progress in Pancreatic Cancer (Zacks)
11:48AM	Recursion (RXRX) Up on Completing REC-994 Study Enrollment (Zacks)
09:26AM	Acadia (ACAD) to Begin Study on ACP-101 for Hyperphagia in PWS (Zacks)
Jun-13-23 10:14AM	AstraZeneca (AZN) Breast Cancer Combo Drug Gets Priority Review (Zacks)
09:40AM	Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year? (Zacks)

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Young Jonathan	Chief Operating Officer	May 01 '24	Sale	20.15	5,000	100,750	258,306	May 02 09:07 PM
Young Jonathan	Chief Operating Officer	Apr 01 '24	Sale	24.38	5,000	121,913	263,306	Apr 03 06:55 PM
Cheng Andrew	President and CEO	Mar 13 '24	Sale	28.33	1,969	55,782	589,447	Mar 15 04:43 PM
White William Richard	Chief Financial Officer	Mar 13 '24	Sale	28.33	724	20,511	49,630	Mar 15 04:44 PM
Yale Catriona	Chief Development Officer	Mar 13 '24	Sale	28.33	723	20,483	77,692	Mar 15 04:45 PM
Young Jonathan	Chief Operating Officer	Mar 13 '24	Sale	28.33	651	18,443	268,306	Mar 15 04:42 PM
Rolph Timothy	Chief Scientific Officer	Mar 13 '24	Sale	28.33	619	17,536	182,558	Mar 15 04:42 PM
Cheng Andrew	President and CEO	Mar 04 '24	Option Exercise	17.17	75,000	1,288,062	666,416	Mar 06 08:14 PM
Yale Catriona	Chief Development Officer	Mar 04 '24	Option Exercise	13.96	20,646	288,124	99,061	Mar 06 08:13 PM
Cheng Andrew	President and CEO	Mar 04 '24	Sale	32.87	75,000	2,465,063	591,416	Mar 06 08:14 PM
Yale Catriona	Chief Development Officer	Mar 04 '24	Sale	35.49	20,646	732,727	78,415	Mar 06 08:13 PM
Young Jonathan	Chief Operating Officer	Mar 01 '24	Option Exercise	0.61	83,321	51,242	268,957	Mar 05 05:16 PM
Cheng Andrew	President and CEO	Jan 02 '24	Option Exercise	0.61	40,000	24,600	590,911	Jan 03 05:00 PM
Young Jonathan	Chief Operating Officer	Dec 27 '23	Option Exercise	6.36	5,414	34,433	190,545	Dec 29 08:30 PM
Young Jonathan	Chief Operating Officer	Dec 27 '23	Sale	24.00	5,414	129,936	185,131	Dec 29 08:30 PM
Cheng Andrew	President and CEO	Dec 14 '23	Sale	20.76	1,628	33,797	550,911	Dec 18 08:37 PM
White William Richard	Chief Financial Officer	Dec 14 '23	Sale	20.76	611	12,684	50,354	Dec 18 08:40 PM
Yale Catriona	Chief Development Officer	Dec 14 '23	Sale	20.76	597	12,394	77,910	Dec 18 08:49 PM
Young Jonathan	Chief Operating Officer	Dec 14 '23	Sale	20.76	543	11,273	185,131	Dec 18 08:39 PM
Rolph Timothy	Chief Scientific Officer	Dec 14 '23	Sale	20.76	514	10,671	182,672	Dec 18 08:29 PM
Cheng Andrew	President and CEO	Dec 11 '23	Option Exercise	6.36	7,405	47,096	559,944	Dec 11 08:59 PM
Cheng Andrew	President and CEO	Dec 11 '23	Sale	20.02	7,405	148,273	552,539	Dec 11 08:59 PM
Cheng Andrew	President and CEO	Dec 08 '23	Option Exercise	6.36	12,873	81,872	473,871	Dec 11 08:59 PM
Graham G. Walmsley	Director	Dec 08 '23	Buy	19.83	100,000	1,982,940	800,000	Dec 11 09:06 PM
Cheng Andrew	President and CEO	Dec 08 '23	Sale	20.01	12,873	257,571	460,998	Dec 11 08:59 PM
Cheng Andrew	President and CEO	Dec 07 '23	Option Exercise	6.36	6,700	42,612	467,698	Dec 11 08:59 PM
Cheng Andrew	President and CEO	Dec 07 '23	Sale	20.02	6,700	134,125	460,998	Dec 11 08:59 PM
Graham G. Walmsley	Director	Dec 01 '23	Buy	16.99	50,000	849,730	700,000	Dec 05 08:37 AM
Graham G. Walmsley	Director	Nov 30 '23	Buy	16.90	50,000	844,835	650,000	Dec 05 08:37 AM
Young Jonathan	Chief Operating Officer	Nov 17 '23	Sale	14.68	30,000	440,259	153,177	Nov 21 05:30 PM
Cheng Andrew	President and CEO	Oct 02 '23	Option Exercise	6.36	25,000	159,000	485,998	Oct 04 08:41 PM
Young Jonathan	Chief Operating Officer	Oct 02 '23	Option Exercise	21.10	490	10,339	183,667	Oct 04 08:33 PM
Cheng Andrew	President and CEO	Oct 02 '23	Sale	47.91	25,000	1,197,827	460,998	Oct 04 08:41 PM
Young Jonathan	Chief Operating Officer	Oct 02 '23	Sale	51.10	490	25,039	183,177	Oct 04 08:33 PM
Yale Catriona	Chief Development Officer	Sep 21 '23	Option Exercise	6.36	5,000	31,800	51,010	Sep 25 08:31 PM
Yale Catriona	Chief Development Officer	Sep 21 '23	Sale	48.07	5,000	240,356	46,010	Sep 25 08:31 PM
Graham G. Walmsley	Director	Sep 19 '23	Buy	26.00	400,000	10,400,000	400,000	May 23 09:55 PM
Cheng Andrew	President and CEO	Sep 13 '23	Sale	50.34	1,682	84,672	460,998	Sep 25 08:36 PM
White William Richard	Chief Financial Officer	Sep 13 '23	Sale	50.34	632	31,815	18,468	Sep 25 08:31 PM
Yale Catriona	Chief Development Officer	Sep 13 '23	Sale	50.34	617	31,060	46,010	Sep 25 08:31 PM
Young Jonathan	Chief Operating Officer	Sep 13 '23	Sale	50.34	562	28,291	183,177	Sep 25 08:28 PM
Rolph Timothy	Chief Scientific Officer	Sep 13 '23	Sale	50.34	531	26,731	150,689	Sep 25 08:30 PM
Cheng Andrew	President and CEO	Sep 01 '23	Option Exercise	6.36	25,000	159,000	487,680	Sep 18 06:48 PM
Cheng Andrew	President and CEO	Sep 01 '23	Sale	49.77	25,000	1,244,248	462,680	Sep 18 06:48 PM
Cheng Andrew	President and CEO	Aug 30 '23	Option Exercise	0.61	15,000	9,225	462,680	Aug 30 07:04 PM
Yale Catriona	Chief Development Officer	Aug 28 '23	Option Exercise	6.36	5,745	36,538	52,372	Aug 30 07:04 PM
Yale Catriona	Chief Development Officer	Aug 28 '23	Sale	49.99	5,745	287,191	46,627	Aug 30 07:04 PM
Graham G. Walmsley	Director	Aug 08 '23	Buy	42.06	25,000	1,051,475	600,000	Aug 10 04:46 PM
Cheng Andrew	President and CEO	Aug 01 '23	Option Exercise	6.36	25,000	159,000	472,680	Aug 03 04:13 PM
Graham G. Walmsley	Director	Aug 01 '23	Buy	43.26	25,000	1,081,525	575,000	Aug 01 07:52 PM
Cheng Andrew	President and CEO	Aug 01 '23	Sale	43.15	25,000	1,078,867	447,680	Aug 03 04:13 PM
Graham G. Walmsley	Director	Jul 28 '23	Buy	42.69	30,000	1,280,709	550,000	Aug 01 07:52 PM
Cheng Andrew	President and CEO	Jul 03 '23	Option Exercise	6.36	25,000	159,000	472,680	Jul 06 08:44 PM
Cheng Andrew	President and CEO	Jul 03 '23	Sale	44.88	25,000	1,122,041	447,680	Jul 06 08:44 PM
Cheng Andrew	President and CEO	Jun 27 '23	Option Exercise	0.61	40,000	24,600	447,680	Jun 27 07:12 PM
Yale Catriona	Chief Development Officer	Jun 23 '23	Sale	50.76	11,000	558,360	46,627	Jun 23 08:06 PM
Yale Catriona	Chief Development Officer	Jun 22 '23	Sale	52.18	11,000	573,935	57,627	Jun 23 08:06 PM
Yale Catriona	Chief Development Officer	Jun 21 '23	Sale	52.26	11,349	593,095	68,627	Jun 23 08:06 PM
White William Richard	Chief Financial Officer	Jun 20 '23	Option Exercise	7.01	17,500	122,658	39,877	Jun 22 05:20 PM
White William Richard	Chief Financial Officer	Jun 20 '23	Sale	55.00	20,777	1,142,735	19,100	Jun 22 05:20 PM
Heyman Tomas J.	Director	Jun 16 '23	Option Exercise	25.04	26,000	651,040	26,000	Jun 21 05:54 PM
Henderson Jane	Director	Jun 16 '23	Option Exercise	7.01	40,000	280,400	40,000	Jun 21 05:47 PM
Rolph Timothy	Chief Scientific Officer	Jun 16 '23	Option Exercise	0.61	40,000	24,400	229,420	Jun 21 05:46 PM
Rolph Timothy	Chief Scientific Officer	Jun 16 '23	Sale	54.78	78,200	4,284,066	151,220	Jun 21 05:46 PM
Henderson Jane	Director	Jun 16 '23	Sale	54.17	40,000	2,166,685	0	Jun 21 05:47 PM
Heyman Tomas J.	Director	Jun 16 '23	Sale	54.67	26,000	1,421,529	0	Jun 21 05:54 PM
Cheng Andrew	President & CEO	Jun 13 '23	Sale	55.16	1,613	88,973	407,680	Jun 15 09:38 PM
White William Richard	Chief Financial Officer	Jun 13 '23	Sale	55.16	606	33,427	22,377	Jun 15 09:41 PM
Yale Catriona	Chief Development Officer	Jun 13 '23	Sale	55.16	591	32,600	79,976	Jun 15 09:29 PM
Young Jonathan	Chief Operating Officer	Jun 13 '23	Sale	55.16	538	29,676	183,739	Jun 15 09:35 PM
Rolph Timothy	Chief Scientific Officer	Jun 13 '23	Sale	55.16	509	28,076	189,420	Jun 15 09:35 PM
Cheng Andrew	President and CEO	Jun 01 '23	Option Exercise	1.46	25,000	36,459	434,293	Jun 05 06:23 PM
Cheng Andrew	President and CEO	Jun 01 '23	Sale	45.10	25,000	1,127,430	409,293	Jun 05 06:23 PM
Graham G. Walmsley	Director	May 19 '23	Buy	42.00	120,000	5,040,000	520,000	May 23 09:55 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

STOK

Stoke Therapeutics Inc

AKRO

Akero Therapeutics Inc

Upgrade your FINVIZ experience